Stefano Kim and colleagues1 report promising activity from a combined neoadjuvant strategy using ezabenlimab (an anti-PD-1) with modified docetaxel, cisplatin, and fluorouracil (mDCF) followed by personalised intensity-modulated radiotherapy with involved-node chemoradiotherapy (INRT) in patients with stage 3 squamous cell anal carcinoma (SCAC). In this phase 2 trial, Kim and colleagues showed high rates of pathological (41 [84%] of 49 evaluable…
[Correspondence] Ezabenlimab with induction chemotherapy and adaptive chemoradiotherapy in stage 3 squamous cell anal carcinoma
The Lancet Oncology | | Bhumesh Tyagi, Leelabati Toppo, Aishwarya Biradar
Topics: cervical-cancer, immunotherapy, chemotherapy, radiation, clinical-trials, research